Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Luminex Q4 Revenues Grow 5 Percent on Assay Sales

Luminex Q4 Revenues Grow 5 Percent on Assay Sales

Feb 02, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Luminex said after the close of the market today that its fourth quarter revenues increased 5 percent year over year driven primarily by strong assay sales.

For the fourth quarter ended Dec. 31, 2014, Luminex reported $58.1 million in revenues compared to $55.2 million in the year-ago period and just below analysts' consensus estimate of $58.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Pause Recommended

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

Science and a Side of Diplomacy

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

New Studies of B.1.1.7

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

PNAS Papers on Acute Kidney Injury, Parental Expression in Horse Placenta, Sea Urchin Microbes

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

What's Popular?

In Business News

  1. DiaSorin to Acquire Luminex for $1.8B

  2. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

  3. 10x Genomics, Bio-Rad Laboratories Subsidiary Celsee Headed to Trial in Single-Cell IP Suit

  4. Sandler Initiates Coverage of Twist Bioscience, Codexis With Overweight Ratings

  5. Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.